Diagnostics
QuantuMDx Group Limited announces a business update and the appointments of Jonathan O’Halloran as Chief Executive Officer and Neil Butler as Chairman of the Board, as the company begins its transition to commercialisation..
As the J.P. Morgan Healthcare Conference winds down for 2020, one of the big topics was the general lack of big deals. Still, there were some general trends and for today, some news.
sphingotec launches a CE-marked point-of-care IVD assay for Proenkephalin (penKid(R)), the company’s proprietary biomarker for real-time assessment of kidney function in critical care settings
Following the acquisition and integration of former Samsung subsidiary Nexus Dx Inc., sphingotec becomes a fully integrated diagnostic solutions provider
It can be a bit difficult to predict exactly what the big stories out of the JP Morgan Healthcare Conference are going to be. There’s no telling if some surprise deal will take the air out of the room, but here’s a look at some of the top presentations.
Test will specifically adjust for isatuximab-induced interference in complete response assessment of multiple myeloma patients
Sphingotec reports study data demonstrating that its proprietary renal function biomarker penKid(R) (Proenkephalin) predicts acute kidney injury (AKI), multi-organ failure and mortality in sepsis patients presenting to the emergency department (ED).
Data from more than 1,200 patients of the PROTECT study demonstrate that high levels of the endothelial function biomarker bio-ADM(R) (bioactive Adrenomedullin) indicate residual congestion of heart failure patients.
At the six-year mark, 90.6% of patients in the Perjeta cohort have not had breast cancer return, compared to 87.8% in the placebo arm. This comes to an absolute benefit of 2.8%.
Owlstone Medical will receive funding to deploy Breath Biopsy® as part of EPHOR
PRESS RELEASES
